News

Eli Lilly (NYSE: LLY) and Merck (NYSE: MRK) have seen their shares rise by over 17% and 5%, respectively, this year while the S&P 500 Health Care Sector Index has dropped 1.7%. What's interesting

If you can buy high-quality dividend stocks when other investors sour on them, you can plant the seeds for robust returns in the future. And that's exactly why it might be worth buying shares of

Dividend growth investing revolves around selecting only the most reliable businesses for your portfolio. This can be measured by consecutive years of dividend growth.

With 51 consecutive years of

Most Americans don't have to wait until they're retired to know that Social Security benefits won't be enough to maintain their current lifestyle. If they pay any attention to retirement planning

Shares of Summit Therapeutics (NASDAQ: SMMT) were up by 61.4% for the week as of late Friday afternoon, according to data provided by S&P Global Market Intelligence. The healthcare stock, which

Fears of a coming recession are probably about as high right now as they have been over the past year. That's because the U.S. Federal Reserve recently predicted an economic downturn would descend

Going, going, gone? That could be the question that Novocure (NASDAQ: NVCR) investors are asking these days. Shares of the oncology company plunged 56% in 2021. The stock slid 2% lower last year

Shares of Karyopharm Therapeutics (NASDAQ: KPTI) were down more than 26% Thursday afternoon after the biotech company released first-quarter earnings and updated its guidance. The stock fell to its

Pfizer (NYSE:PFE) confirmed this week what everyone has been expecting. COVID-19 vaccine sales are falling drastically. The company reported a 77% drop in Comirnaty sales in the first quarter

Regeneron Pharmaceuticals (NASDAQ: REGN), a large-cap biotechnology company, is under heavy pressure today. Specifically, the biotech's stock was down by an unsightly 6.5% on heavy volume as of

Image source: The Motley Fool.

Karyopharm Therapeutics (NASDAQ: KPTI)Q1 2023 Earnings CallMay 04, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Image source: The Motley Fool.

Zoetis (NYSE: ZTS)Q1 2023 Earnings CallMay 04, 2023, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com

Stag Industrial (NYSE: STAG) and Vertex Pharmaceuticals (NASDAQ: VRTX) are off to a good start this year, and some industry tailwinds look to really boost shares in the coming years. Stag, which

Healthcare stocks always make a great addition to long-term portfolios. They offer you the potential to benefit from steady earnings growth over time. After all, regardless of the economic

Investors are often encouraged when one of their companies bulks up by acquiring a peer. But that sentiment can turn sour if the takeover target stumbles.

This was the impetus behind Amgen's

Image source: The Motley Fool.

Amarin Plc (NASDAQ: AMRN)Q1 2023 Earnings CallMay 03, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Investors were ready for declines in AbbVie's (NYSE: ABBV) blockbuster immunology drug Humira. The product now is facing competition in the U.S. So, seeing a 26% drop in Humira's U.S. first-quarter

Shares of the Illinois-based drugmaker Eli Lilly (NYSE: LLY) were up by 6% on heavy volume as of 1:45 p.m. ET Wednesday.

What sparked this latest rally? Ahead of the opening bell, Lilly announced

Shares of ImmunoGen (NASDAQ: IMGN) were up by 139% Wednesday morning after the company announced positive trial data concerning an ovarian cancer drug the company has in its pipeline. The biotech

High-quality dividend stocks are normally a great addition to any portfolio regardless of market conditions. However, this exceedingly risk-averse market has punished even elite dividend-paying

Had you bought Vertex Pharmaceuticals (NASDAQ: VRTX) shares 10 years ago, you'd be sitting pretty right now. The drugmaker soundly outperformed the market over that period thanks to its success in